Beam Therapeutics will present new BEAM-101 data for sickle cell disease at EHA2025, detailing safety and efficacy in 17 patients. Beam Therapeutics Inc. has announced that it will present updated ...

A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has ...

BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported data highlighting its optimized, closed and automated manufacturing process for its base ...

Beam Therapeutics Inc. (NASDAQ:BEAM) on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD) at the 2025 Alpha-1 ...

BEAM-101 Phase 1/2 trial data showed HbF levels exceeded 60%, HbS dropped below 40%, with normalized hemolysis markers. Preclinical BEAM-103 results indicated rapid HbF induction and long-term ...

BofA analyst Alec Stranahan upgraded Beam Therapeutics (BEAM) to Buy from Neutral with an unchanged price target of $42 following data for BEAM-302, one of its lead gene editing assets that treats ...

In contrast, some methods that use machine learning models to make predictions about the beam distribution can take thousands of data points to train, while other reconstruction methods can take ...

Beam Therapeutics has presented the first clinical data on its base editing technology. All four sickle cell disease patients in the efficacy cohort had fetal hemoglobin levels above Beam’s ...

Beam plans further dose escalation and will report new trial data in H2 2025, while also enrolling patients with liver diseases. Unlock your all-in-one trading dashboard with real-time alerts ...

Well, none of the patients who were given BEAM-101 had this issue at all. If this data was revealed, then why should investors care now at all? It is because this was only a set of results ...